Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score

Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer--a problem still to be solved

(2014) M. Schmidt et al.   ANNALS OF ONCOLOGY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses

(2013) Roman Rouzier et al.   BREAST CANCER RESEARCH AND TREATMENT

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

(2013) Josh J. Carlson et al.   BREAST CANCER RESEARCH AND TREATMENT

Precision Oncology in Breast Cancer: Better than Ever, or Less than Before?

(2013) Adam Brufsky   Breast Journal

Is OncotypeDX Recurrence Score (RS) of Prognostic Value Once HER2-Positive and. Low-ER Expression Patients are Removed?

(2013) Meghan Milburn et al.   Breast Journal

Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation

(2013) Julianne R. Biroschak et al.   Breast Journal

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

(2013) Molly E Klein et al.   MODERN PATHOLOGY

Molecular Pathology of Breast Cancer

(2012) Kimberly H. Allison   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Interobserver Agreement Among Pathologists for Semiquantitative Hormone Receptor Scoring in Breast Carcinoma

(2012) David A. Cohen et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues

(2012) V. M. Neumeister et al.   JNCI-Journal of the National Cancer Institute

High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines

(2012) Maria E Vergara-Lluri et al.   MODERN PATHOLOGY

The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor and HER2 expression in invasive breast carcinoma

(2012) Isil Z Yildiz-Aktas et al.   MODERN PATHOLOGY

Semi-quantitative immunohistochemical assay versus oncotype DX® qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study

(2012) James A Kraus et al.   MODERN PATHOLOGY

Impact of Progesterone Receptor Semiquantitative Immunohistochemical Result on Oncotype DX Recurrence Score

(2012) Beth Z. Clark et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting

(2012) J. U. Blohmer et al.   JOURNAL OF MEDICAL ECONOMICS

The challenge and importance of standardizing pre-analytical variables in surgical pathology specimens for clinical care and translational research

(2011) DG Hicks et al.   BIOTECHNIC & HISTOCHEMISTRY

Pathological work up of the primary tumor: Getting the proper information out of it

(2011) Giuseppe Viale   BREAST

Routine pathologic parameters can predict Oncotype DXTM recurrence scores in subsets of ER positive patients: who does not always need testing?

(2011) K. H. Allison et al.   BREAST CANCER RESEARCH AND TREATMENT

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score

(2011) S Sahebjam et al.   BRITISH JOURNAL OF CANCER

High False-Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study

(2011) David J. Dabbs et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

(2011) Jack Cuzick et al.   JOURNAL OF CLINICAL ONCOLOGY

A mitotically active, cellular tumor stroma and/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas

(2011) Geza Acs et al.   MODERN PATHOLOGY

The Effect of Oncotype DX Recurrence Score on Treatment Recommendations for Patients with Estrogen Receptor-Positive Early Stage Breast Cancer and Correlation with Estimation of Recurrence Risk by Breast Cancer Specialists

(2011) J. E. Joh et al.   ONCOLOGIST

Proliferation (Ki-67 and Phosphohistone H3) and Oncotype DX Recurrence Score in Estrogen Receptor-positive Breast Cancer

(2011) Daron J. Williams et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers

(2010) Catherine M. Kelly et al.   CANCER

A Lower Allred Score for Progesterone Receptor Is Strongly Associated With a Higher Recurrence Score of 21-Gene Assay in Breast Cancer

(2010) Ping Tang et al.   CANCER INVESTIGATION

HER-2/neu Assessment in Breast Cancer Using the Original FDA and New ASCO/CAP Guideline Recommendations

(2008) Matteo Brunelli et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers

(2008) Jan P. A. Baak et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemotherapy Use for Hormone Receptor–Positive, Lymph Node–Negative Breast Cancer

(2008) Michael J. Hassett et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

(2008) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Histopathologic variables predict Oncotype DX™ Recurrence Score

(2008) Melina B Flanagan et al.   MODERN PATHOLOGY

Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry

(2008) Hadi Yaziji et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY